Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

• Wittawat Chantkran,
• Ya-Ching Hsieh,
• Daniella Zheleva,
• Sheelagh Frame,
• Helen Wheadon,
• Mhairi Copland

Affiliations

Wittawat Chantkran

Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow

Ya-Ching Hsieh

Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow

Daniella Zheleva

Cyclacel Limited

Sheelagh Frame

Cyclacel Limited

Helen Wheadon

Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow

Mhairi Copland

Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow